Patents by Inventor Norbert Hilf
Norbert Hilf has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20140271692Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumour-associated T-helper cell peptide epitopes, alone or in combination with other tumour-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumour immune responses. The present invention relates to novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumour cells which can be used in vaccine compositions for eliciting anti-tumour immune responses.Type: ApplicationFiled: December 23, 2013Publication date: September 18, 2014Applicant: IMMATICS BIOTECHNOLOGIES GMBHInventors: Harpreet SINGH, Steffen WALTER, Toni WEINSCHENK, Norbert HILF, Oliver SCHOOR, Claudia TRAUTWEIN
-
Patent number: 8669230Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-helper cell peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumor immune responses. The present invention relates to novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells which can be used in vaccine compositions for eliciting anti-tumor immune responses.Type: GrantFiled: October 29, 2010Date of Patent: March 11, 2014Assignee: Immatics Biotechnologies GmbHInventors: Harpreet Singh, Steffen Walter, Toni Weinschenk, Norbert Hilf, Oliver Schoor, Claudia Lemmel
-
Patent number: 8653035Abstract: The present invention relates to immunotherapeutic peptides and their use in immunotherapy, in particular the immunotherapy of cancer. The present invention discloses tumor-associated T-helper cell peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumor immune responses. In particular, the composition of the peptides of the present invention can be used in vaccine compositions for eliciting anti-tumor immune responses against gliomas.Type: GrantFiled: August 17, 2012Date of Patent: February 18, 2014Assignee: Immatics Biotechnologies GmbHInventors: Toni Weinschenk, Oliver Schoor, Claudia Trautwein, Norbert Hilf, Steffan Walter, Harpreet Singh
-
Publication number: 20130309193Abstract: The present invention relates to immunotherapeutic peptides and their use in immunotherapy, in particular the immunotherapy of cancer. The present invention discloses tumor-associated T-helper cell peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumor immune responses. In particular, the composition of the peptides of the present invention can be used in vaccine compositions for eliciting anti-tumor immune responses against gliomas.Type: ApplicationFiled: March 15, 2013Publication date: November 21, 2013Applicant: IMMATICS BIOTECHNOLOGIES GMBHInventors: Toni WEINSCHENK, Oliver SCHOOR, Claudia TRAUTWEIN, Norbert HILF, Steffan WALTER, Harpreet SINGH
-
Publication number: 20130004456Abstract: The present invention relates to immunotherapeutic peptides and their use in immunotherapy, in particular the immunotherapy of cancer. The present invention discloses tumor-associated T-helper cell peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumor immune responses. In particular, the composition of the peptides of the present invention can be used in vaccine compositions for eliciting anti-tumor immune responses against gliomas.Type: ApplicationFiled: August 17, 2012Publication date: January 3, 2013Applicant: IMMATICS BIOTECHNOLOGIES GMBHInventors: Toni WEINSCHENK, Oliver SCHOOR, Claudia TRAUTWEIN, Norbert HILF, Steffen WALTER, Harpreet SINGH
-
Patent number: 8318677Abstract: The present invention relates to immunotherapeutic peptides and their use in immunotherapy, in particular the immunotherapy of cancer. The present invention discloses tumor-associated T-helper cell peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumor immune responses. In particular, the composition of the peptides of the present invention can be used in vaccine compositions for eliciting anti-tumor immune responses against gliomas.Type: GrantFiled: October 1, 2009Date of Patent: November 27, 2012Assignee: Immatics Biotechnologies GmbHInventors: Toni Weinschenk, Oliver Schoor, Claudia Trautwein, Norbert Hilf, Steffen Walter, Harpreet Singh
-
Publication number: 20120141517Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 30 peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.Type: ApplicationFiled: January 9, 2012Publication date: June 7, 2012Applicant: IMMATICS BIOTECHNOLOGIES GMBHInventors: Toni Weinschenk, Oliver Schoor, Claudia Trautwein, Norbert Hilf, Steffan Walter, Harpreet Singh
-
Patent number: 8119139Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 30 peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.Type: GrantFiled: October 1, 2009Date of Patent: February 21, 2012Assignee: Immatics Biotechnologies GmbHInventors: Toni Weinschenk, Oliver Schoor, Claudia Trautwein, Norbert Hilf, Steffen Walter, Harpreet Singh
-
Patent number: 8080634Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-helper cell peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumor immune responses. The present invention relates to novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells which can be used in vaccine compositions for eliciting anti-tumor immune responses.Type: GrantFiled: July 25, 2008Date of Patent: December 20, 2011Assignee: Immatics Biotechnologies GmbHInventors: Harpreet Singh, Steffen Walter, Toni Weinschenk, Norbert Hilf, Oliver Schoor, Claudia Lemmel
-
Patent number: 7994276Abstract: The present invention relates to immunotherapeutic peptides and their use in immunotherapy, in particular the immunotherapy of cancer. The present invention discloses tumor-associated T-helper cell peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumor immune responses. In particular, the composition of the peptides of the present invention can be used in vaccine compositions for eliciting anti-tumor immune responses against colorectal cancer.Type: GrantFiled: July 25, 2008Date of Patent: August 9, 2011Assignee: Immatics Biotechnologies GmbHInventors: Harpreet Singh, Steffen Walter, Toni Weinschenk, Norbert Hilf, Oliver Schoor, Claudia Trautwein, Peter Lewandrowski
-
Publication number: 20110117117Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumour-associated T-helper cell peptide epitopes, alone or in combination with other tumour-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumour immune responses. The present invention relates to novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumour cells which can be used in vaccine compositions for eliciting anti-tumour immune responses.Type: ApplicationFiled: October 29, 2010Publication date: May 19, 2011Applicant: Immatics Biotechnologies GmbHInventors: Harpreet Singh, Steffen Walter, Toni Weinschenk, Norbert Hilf, Oliver Schoor, Claudia Lemmel
-
Publication number: 20110002963Abstract: The present invention relates to immunotherapeutic peptides and their use in immunotherapy, in particular the immunotherapy of cancer. The present invention discloses tumor-associated T-helper cell peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumor immune responses. In particular, the composition of the peptides of the present invention can be used in vaccine compositions for eliciting anti-tumor immune responses against gliomas.Type: ApplicationFiled: October 1, 2009Publication date: January 6, 2011Applicant: IMMATICS BIOTECHNOLOGIES GMBHInventors: Toni WEINSCHENK, Oliver Schoor, Claudia Trautwein, Norbert Hilf, Steffen Walter, Harpreet Singh
-
Publication number: 20100158931Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 30 peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.Type: ApplicationFiled: October 1, 2009Publication date: June 24, 2010Applicant: IMMATICS BIOTECHNOLOGIES GMBHInventors: Toni Weinschenk, Oliver Schoor, Claudia Trautwein, Norbert Hilf, Steffen Walter, Harpreet Singh
-
Publication number: 20090148400Abstract: The present invention relates to immunotherapeutic peptides and their use in immunotherapy, in particular the immunotherapy of cancer. The present invention discloses tumour-associated T-helper cell peptide epitopes, alone or in combination with other tumour-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumour immune responses. In particular, the composition of the peptides of the present invention can be used in vaccine compositions for eliciting anti-tumour immune responses against colorectal cancer.Type: ApplicationFiled: July 25, 2008Publication date: June 11, 2009Applicant: Immatics Biotechnologies GmhHInventors: Harpreet Singh, Steffen Walter, Toni Weinschenk, Norbert Hilf, Oliver Schoor, Claudia Lemmel
-
Publication number: 20090136528Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumour-associated T-helper cell peptide epitopes, alone or in combination with other tumour-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumour immune responses. The present invention relates to novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumour cells which can be used in vaccine compositions for eliciting anti-tumour immune responses.Type: ApplicationFiled: July 25, 2008Publication date: May 28, 2009Applicant: Immatics Biotechnologies GmhHInventors: Harpreet SINGH, Steffen WALTER, Toni WEINSCHENK, Norbert HILF, Oliver Schoor, Claudia Lemmel
-
Publication number: 20090123489Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 11 novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.Type: ApplicationFiled: July 25, 2008Publication date: May 14, 2009Applicant: Immatics Biotechnologies GmhHInventors: Toni WEINSCHENK, Oliver Schoor, Claudia Trautwein, Norbert Hilf, Steffen Walter, Harpreet Singh
-
Publication number: 20090004213Abstract: The present invention relates to methods of treating cancer in a mammal comprising administering to the mammal a combination therapy comprising a vaccine and a multi-kinase inhibitor, wherein the vaccine comprises an isolated tumor associated peptide having the ability to bind to a molecule of the human major histocompatibility complex (MHC) class-I or class-II. Preferably the multi-kinase inhibitor is sunitinib malate and/or sorafenib tosylate or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: March 25, 2008Publication date: January 1, 2009Applicant: Immatics Biotechnologies GmbHInventors: Harpreet Singh, Niels Emmerich, Norbert Hilf, Steffen Walter, Toni Weinschenk
-
Publication number: 20060171988Abstract: The present invention relates to pharmaceutical compositions for the improved activation of cells of the immune system that comprise a biocompatible implantable and an active pharmaceutical ingredient to be integrated into said foam, wherein said composition specifically activates cells of the immune system. In one preferred embodiment, said active pharmaceutical ingredient is selected from endogenous antigens that are selected from tumor-associated antigens. Said foam material can be implanted into a subject in order to produce the pharmaceutical composition in situ. Preferably, said pharmaceutical composition can be present in the form of an artificial lymph node, wherein said artificial lymph node functions as a reservoir for cells of the immune system. The invention also relates to methods for improved immunotherapy, in particular cancer immunotherapy.Type: ApplicationFiled: January 28, 2005Publication date: August 3, 2006Inventors: Norbert Hilf, Juergen Pinocy